Visceral Adiposity Index and Anti-VEGF Resistance in Diabetic Macular Edema

A retrospective cohort study of 298 patients with type 2 diabetes and center-involved diabetic macular edema initiating anti-VEGF therapy between January 2022 and December 2023. The research analyzes the Visceral Adiposity Index as a prognostic marker for treatment resistance, with 47.0% of patients classified as non-responders. The study was authored by Mi Chen and shared via figshare.

Use Cases

• Analyze the association between baseline Visceral Adiposity Index scores and treatment resistance classification to identify high-risk patients.
• Validate the prognostic performance of the VAI cut-off of 2.50 using the reported AUC of 0.73 for predicting anti-VEGF therapy failure.
• Model time-to-positive functional response using Kaplan-Meier analysis based on patient VAI stratification.
• Calculate adjusted odds ratios for treatment response using multivariable logistic regression with VAI and other confounders.

Strengths

• Includes data from 298 patient records for analysis.
• Provides a specific temporal coverage from January 2022 to December 2023.
• Reports concrete statistical results, including an AUC of 0.73 and an optimal VAI cut-off of 2.50.

Limitations

• The dataset is very small at 16.2 KB, containing a research article rather than raw tabular data.
• Sample data and column definitions are unavailable, limiting direct analytical use.
• As a retrospective single-center study, findings may have geographic and selection biases.

Provenance

Source

figshare, author Mi Chen.

Collection Method

Retrospective cohort study analyzing patient records.

Time Range

January 2022 to December 2023.

Freshness

Last updated in March 2026.

Geography

null